VanEck Australian Floating Rate ETF vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.43 (market cap $6.04B). The key difference: VanEck Australian Floating Rate ETF is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| FLOT | IOVA | |
|---|---|---|
Market Cap | $11.24B | $6.04B |
Volume | 1,872,962 | 14,805,993 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $14.82 |
52-Week Low | $50.72 | $1.81 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | — | $5.97B |
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.91 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent dividend distributions of $0.17-$0.18 highlight income generation. The ETF benefits from floating rate exposure amid Fed tightening cycles, though concentration risk in bank holdings (47% exposure) warrants attention.
Outlook remains tied to interest rate trajectory, with FLOT positioned to benefit from higher rates. Key risks include bank sector concentration and Fed policy shifts. The current technical weakness suggests cautious near-term momentum despite the floating rate advantage in rising rate environments.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →